7 JCI-accredited hospitals · 45+ hospitals & clinics · 90+ countries served · 24/7 multilingual support
Blood Health

Heart, Liver and Hormone Screening in Thalassemia: Why Long-Term Monitoring Matters

23 min read
Heart, Liver and Hormone Screening in Thalassemia: Why Long-Term Monitoring Matters

Key Takeaways

  • The body has no way to excrete excess iron, so every transfusion adds iron that stays until a chelating medicine removes it.
  • Ferritin tracks total body iron only roughly and heart iron poorly, which is why cardiac MRI T2* is used to measure heart iron directly.
  • The liver loads first and most, but the heart and hormone glands tolerate iron far less well and fail with much smaller deposits.
  • Standard HbA1c can under-read blood sugar in transfused people because transfused red cells do not live a normal lifespan, so teams often use glucose tolerance tests instead.
  • Carriers with thalassemia trait do not accumulate iron and are not usually enrolled in organ complication screening.
  • Screening results also monitor the safety of iron-removal medicines themselves, including kidney function, blood counts, hearing and vision.
Quick Answer

People with thalassemia, especially those who receive regular transfusions, are usually offered scheduled checks of the heart, liver and hormone-producing glands because excess iron settles in these organs silently for years before symptoms appear. Screening typically combines blood tests such as ferritin with MRI iron measurement, heart imaging and endocrine blood work, and the results guide how the treating team adjusts iron-removal therapy over time.

Marisol has had a blood transfusion about once a month since she was two. She can read a hemoglobin result faster than most nurses. What she could not see, until a cardiac MRI showed it, was iron quietly gathering in the muscle of her heart. She felt fine. Her ferritin had looked acceptable for years.

That gap between feeling fine and being fine is the whole reason thalassemia complication screening exists. Iron does not announce itself. It accumulates one transfusion at a time, then one year at a time, and the organs it favors, heart, liver, pituitary, thyroid, pancreas, tend to stay quiet until the damage is advanced.

This article explains what each check is looking for, how the tests actually work, who is monitored most closely and how the results shape treatment. The decisions, always, sit with the team that knows your history.

Why thalassemia complication screening matters more than the diagnosis itself

Thalassemia is an inherited condition in which the body makes too little of one of the protein chains that build hemoglobin, the molecule inside red blood cells that carries oxygen. The result is anemiatoo few healthy red cells, and, in the more severe forms, a dependence on transfused blood to stay well. The diagnosis is usually made once, often in childhood. The complications are a lifelong project.

The reason is iron. The human body has no active mechanism for excreting excess iron; it can slow absorption from food, but it cannot open a drain. Every unit of transfused red cells arrives with its own iron cargo, and when those cells wear out the iron stays behind. The National Heart, Lung, and Blood Institute describes iron overload as a central long-term problem for people who receive regular transfusions, and notes that even people who are rarely transfused can absorb too much iron from food because the bone marrow, straining to make red cells, signals the gut to take up more.

Where that iron goes is not random. The liver stores it first and in the largest amounts. Heart muscle and the hormone-producing glands, pituitary, thyroid, parathyroid and the insulin-producing cells of the pancreas, take up smaller quantities but tolerate them poorly. Damage in those tissues tends to be quiet for years, then serious.

Screening, then, is not about confirming thalassemia. It is about catching organ iron and organ strain while both are still controllable, and using what is found to fine-tune iron-removal therapy before symptoms ever arrive. That shift, from reacting to preventing, is what has reshaped adult life with thalassemia, and it depends entirely on showing up for the tests.

How does iron overload in thalassemia actually damage organs?

Iron in the bloodstream normally travels bound to a carrier protein called transferrin, which delivers it safely to cells that need it. When transfusions keep adding iron, transferrin runs out of seats. The overflow circulates as “free” iron, and free iron behaves badly: it slips into cells through channels meant for calcium and other minerals, and once inside it catalyzes reactions that generate reactive oxygen species, unstable molecules that tear at cell membranes, proteins and DNA.

Doctor consulting with adult male patient in clinic: How does iron overload in thalassemia actually damage organs?

Each organ fails in its own way. In the liver, iron-loaded cells trigger inflammation and, over time, scarring called fibrosis; advanced scarring is cirrhosis, which raises the long-term risk of liver cancer. In the heart, iron settles inside muscle cells and interferes with both pumping strength and the electrical wiring that keeps the rhythm steady, which is why heart iron can show up as an irregular heartbeat before it shows up as breathlessness. In the endocrine glands, relatively small deposits are enough to switch off hormone production, because these glands are tiny and have little reserve.

Two features of this process explain the shape of modern screening. First, the organs load at different rates and in different orders, the liver fills early, the heart later, and the amount of iron in one does not reliably predict the amount in another. Second, the standard blood marker, ferritin (a protein that stores iron and leaks into the blood roughly in proportion to body stores), is a rough guide at best. Inflammation, infection and liver disease all push ferritin up or down independently of iron, so a reassuring ferritin can coexist with a heavily loaded heart.

That mismatch is the entire case for looking directly at the organs rather than trusting a single number.

What does a thalassemia test diagnose, and how is that different from complication screening?

People often search this question expecting one test. In practice there are two very different kinds.

The diagnostic workup answers “does this person have thalassemia, and which type?” A complete blood count shows small, pale red cells and a low hemoglobin. Because iron deficiency looks similar on that first test, iron studies are usually checked alongside it. Hemoglobin electrophoresis, or a related laboratory method, then separates the different hemoglobin types and reveals the pattern typical of alpha or beta thalassemia; DNA testing can pinpoint the specific gene change, which matters for predicting severity and for family planning. The CDC notes that in the United States many affected babies are identified through routine newborn screening, and prenatal testing is available for families who carry the trait.

This workup also settles an important distinction. Someone with thalassemia trait, a carrier, with one altered gene, typically has mild or no anemia, needs no transfusions and does not accumulate iron. Someone with thalassemia major, also called transfusion-dependent thalassemia, cannot maintain a safe hemoglobin without regular transfusions. In between sits thalassemia intermedia, or non-transfusion-dependent thalassemia, where transfusions are occasional and iron builds more slowly through the gut.

Complication screening is the second kind of testing, and it is for the second and third groups. It does not ask whether you have thalassemia. It asks what the condition and its treatment are doing to your heart, liver, glands and bones this year, compared with last year. The tools differ: MRI rather than electrophoresis, echocardiography rather than a blood film, and so does the rhythm: the diagnosis is made once, whereas screening repeats on a schedule your team sets and revises for life.

Heart screening: why cardiologists and hematologists share this patient

Heart disease from iron has historically been the most feared complication of transfusion-dependent thalassemia, and the reason is timing. Heart iron can climb for years without symptoms, then tip abruptly into heart failure or dangerous rhythm problems. The screening program is built to find it before the tipping point.

Doctors explaining heart anatomy model to female patient: Heart screening: why cardiologists and hematologists share this pa

Three tools do most of the work. An electrocardiogram (ECG) records the heart’s electrical activity through skin electrodes and can reveal rhythm disturbances or conduction changes that iron causes. An echocardiogram is an ultrasound of the heart that measures how strongly the chambers squeeze, how the valves function and whether pressure in the lung circulation is raised, pulmonary hypertension being a recognized concern, particularly in people whose spleen has been removed. Neither test, however, measures iron itself.

That is the job of cardiac MRI using a technique called T2* (pronounced “T2 star”). Iron shortens a particular magnetic signal in tissue, so the more iron in the heart muscle, the faster that signal decays. The scanner converts the decay time into a number, and the number tells the team whether heart iron is normal, mildly raised or in a range where risk climbs steeply. Because the measurement is direct, it can catch a loaded heart in someone whose ferritin looks reassuring, exactly the situation in the opening of this article. The NHLBI describes MRI as the standard way to measure iron in both heart and liver.

The heart battery is repeated on a cycle the treating team sets, tightened when iron is high or pumping function has slipped. Young children are generally not scanned until they can lie still and until enough years of transfusion have passed for heart loading to be plausible; the starting age is a clinical judgment, not a rule.

Liver screening: ferritin, MRI iron and hepatitis checks, and why all three are needed

The liver is where the body parks most of its excess iron, so it is also where the earliest and clearest measurements come from. Liver screening in thalassemia layers several tests because each sees a different part of the problem.

Ferritin is the everyday marker, drawn from routine blood samples. Its strength is convenience: it tracks the trend of body iron over months and flags when things are drifting the wrong way. Its weakness is noise. Ferritin rises with any infection or inflammation and can fall with liver injury, so a single value rarely changes a decision; the trend across several values does.

Liver iron concentration measured by MRI gives the direct figure that ferritin only estimates. The same T2*-type physics used for the heart, or a related method called R2, converts the scan into an iron concentration per gram of liver tissue. This once required a needle biopsy; MRI has largely replaced it because it is non-invasive, repeatable and samples the whole organ rather than one core.

Liver function tests, enzymes such as ALT and AST that leak from stressed liver cells, show whether iron is actively causing injury. Hepatitis B and C serology matters because people transfused before modern donor screening carry a higher chance of having acquired these viruses, and viral hepatitis plus iron is a far more dangerous combination than either alone. Where scarring is suspected, ultrasound or elastography (a scan that measures liver stiffness) may be added, and people with cirrhosis or chronic hepatitis are generally followed with periodic imaging for liver cancer.

The NHS lists liver damage among the main long-term complications of thalassemia and describes regular blood tests to monitor iron as standard care. What the numbers mean for you, whether iron-removal therapy needs adjusting, whether a liver specialist should be involved, is a conversation for your treating team.

Hormone screening: the small glands that fail quietly

Endocrine complications are among the most common long-term problems in adults with thalassemia major, yet they are also the easiest to miss, because each creeps in slowly and mimics ordinary life. Tiredness, feeling cold, low mood, weight change, a stalled growth spurt, none of these shouts “gland.” Screening replaces guesswork with blood tests.

The pituitary, a pea-sized gland at the base of the brain, is unusually sensitive to iron. When it falters, the signals it sends to the ovaries and testes weaken, producing hypogonadism, low sex-hormone output. In teenagers this appears as delayed or arrested puberty; in adults as absent periods, low libido, infertility and, over time, thinning bones. Screening measures sex hormones and the pituitary hormones that drive them, alongside careful growth tracking in children.

The pancreas comes next. Iron in the insulin-producing cells, combined with iron-related insulin resistance in the liver, leads to a form of diabetes. A detail worth knowing: the standard HbA1c test can under-read in transfused people, because it assumes red cells live a normal lifespan and transfused cells do not. Teams therefore often rely on fasting glucose or an oral glucose tolerance test instead.

Thyroid and parathyroid glands round out the panel. An underactive thyroid slows metabolism; underactive parathyroids let blood calcium fall, causing tingling, cramps and, when severe, seizures. Both are checked with simple blood tests. Bone density scanning (DEXA, a low-dose X-ray that measures bone mineral) is usually folded into the same review, because hormone deficiency, marrow expansion and iron together make osteoporosis common at ages when it would otherwise be rare.

Mayo Clinic and the NHS both list slow growth, delayed puberty and diabetes among recognized complications. Finding them early gives the team the option to act before they cause lasting harm.

Thalassemia complication screening at a glance

No two programs are identical, and intervals are set by the treating team according to age, transfusion history and previous results. The table below shows what a comprehensive review for a transfused adult typically covers and why each piece is there.

Organ or system What is checked How Why it matters
Heart Iron content, pumping function, rhythm, lung-circulation pressure Cardiac MRI T2*, echocardiogram, ECG Heart iron is silent until late and can cause heart failure or arrhythmia
Liver Iron concentration, injury, viral hepatitis, scarring MRI liver iron, ferritin trend, liver enzymes, hepatitis B/C tests, ultrasound or elastography when indicated Largest iron store; fibrosis and hepatitis raise cancer risk
Pituitary and gonads Sex hormones, pituitary drive, growth and pubertal progress Blood hormone panel, growth charts in children Delayed puberty, infertility and bone loss follow pituitary iron
Pancreas Glucose handling Fasting glucose or oral glucose tolerance test (HbA1c can mislead after transfusion) Iron-related diabetes develops quietly
Thyroid and parathyroid Thyroid hormones, calcium, parathyroid hormone Blood tests Underactivity causes fatigue, cold intolerance, cramps or seizures
Bone Bone mineral density, vitamin D DEXA scan, blood tests Osteoporosis and fractures appear early in thalassemia
Treatment safety Kidney function, blood counts, hearing, vision Blood and urine tests, audiology, eye checks Iron-removal medicines carry their own side effects that need tracking

Two observations about this table. It is longer than most people expect, which is why specialist centers usually cluster the tests into an annual review day rather than scattering them. And it is a living document: a normal result buys reassurance for now, not forever, because iron keeps arriving with every transfusion.

Who is monitored intensively, and who is usually asked to wait

The intensity of thalassemia complication screening tracks one variable more than any other: how fast iron is entering the body.

People with transfusion-dependent thalassemia sit at the top of the list. Their iron intake is measured in units of blood, and the full program, heart, liver, endocrine, bone and treatment-safety checks, applies from childhood onward, with imaging added once a child is old enough to cooperate and old enough for organ loading to be plausible. Growth, weight and pubertal milestones are tracked from the very beginning, because a slowing growth curve is often the first visible clue that iron or under-transfusion is taking a toll.

People with non-transfusion-dependent thalassemia are monitored too, but the pattern differs. Their iron arrives through the gut, so it accumulates more slowly and shows up later in life. Ferritin is a particularly poor guide in this group, it tends to understate liver iron, which is one reason MRI liver measurement remains part of their care. Their complication profile also leans toward problems of chronic anemia and marrow expansion: pulmonary hypertension, blood clots, leg ulcers, gallstones and masses of blood-forming tissue outside the marrow. Screening is tailored accordingly.

People who have had their spleen removed, whatever their thalassemia type, carry added risks of serious infection and clotting and are usually followed more closely.

Carriers, people with thalassemia trait, are generally not enrolled in complication screening at all. They do not accumulate iron and do not develop organ complications from the trait itself. Their conversations with clinicians center on avoiding unnecessary iron supplements and on genetic counseling before having children, not on MRI scans.

Pregnancy is a special case. Because the heart works harder in pregnancy, women with thalassemia are usually offered a cardiac assessment and an iron-therapy review before conceiving, with the plan agreed between hematology, cardiology and obstetric teams.

Does thalassemia get worse with age?

The gene change itself does not change. What changes is the accumulated burden it creates, and honesty about that is the best argument for lifelong monitoring.

Consider what stacks up over decades in transfusion-dependent thalassemia. Each year adds a fixed number of transfusions and their iron. Each year of imperfectly controlled iron adds a little more to the liver and heart. Hormone glands, once damaged, rarely recover fully, so deficiencies acquired in adolescence carry into adulthood. Bone lost in the twenties is not easily rebuilt. Layer on the ordinary changes of aging, stiffer arteries, a heart with less reserve, and the same iron load becomes more dangerous at fifty than it was at twenty. Mayo Clinic notes that the severe forms usually reveal themselves within the first two years of life; the complications, by contrast, are largely an adult story.

Non-transfusion-dependent thalassemia often looks like the reverse: a childhood that seemed relatively mild, followed by complications that surface in the thirties and forties as slow gut iron absorption finally reaches a threshold and years of chronic anemia strain the heart and lungs. People in this group are sometimes lost to follow-up precisely because they felt well for so long.

There is a hopeful half to this answer. Complications are not inevitable consequences of age; they are largely consequences of iron and of gaps in care. Adults who have grown up under structured monitoring and consistent iron-removal therapy reach middle age with far fewer of the problems that once defined the condition. The vulnerable moment, clinicians repeatedly observe, is the handover from pediatric to adult services, when appointments thin out and a person who has never felt ill decides the annual review is optional.

What are the major symptoms of thalassemia, and why screening cannot wait for them

The presenting features of thalassemia belong mostly to the anemia. Mayo Clinic describes fatigue, weakness, pale or yellow-tinged skin, slow growth in children, swelling of the abdomen from an enlarged spleen or liver, and dark urine from the breakdown of fragile red cells. In the severe forms these appear early in life and are usually what prompts the diagnosis.

Some people also ask about the facial appearance historically associated with thalassemia major. The explanation is mechanical rather than mysterious. When the marrow works overtime to produce red cells, it expands, and expanding marrow inside the bones of the skull and face can broaden the forehead and cheekbones and alter the alignment of the jaw and teeth. These changes were common when transfusion started late or was given sparingly. Where regular transfusion begins early and keeps the hemoglobin steady, the marrow has no reason to over-expand and such changes are far less frequent. They are a marker of the condition’s history, not of the person.

None of this, however, is what complication screening looks for. The symptoms of iron overload are late symptoms. By the time someone notices breathlessness on stairs, swollen ankles or a fluttering heartbeat, cardiac iron has usually been high for years. By the time a young man realizes puberty has stalled, pituitary damage is established. Liver fibrosis produces essentially no symptoms until it is advanced.

This is the fundamental difference between symptom-led medicine and surveillance medicine. Screening is deliberately performed on people who feel well, because feeling well is exactly when intervention has the most to offer. If you already carry a thalassemia diagnosis, the absence of symptoms is a reason to keep the appointment, not to cancel it.

How the results steer iron-removal therapy, and what the weeks after a review usually look like

Screening results are not filed away; they set the next year’s treatment. The treatment in question is iron chelation, medicines called iron chelators that bind excess iron so the body can pass it out in urine or stool. Several exist, taken by mouth or given as a slow infusion under the skin, and they go by generic names such as deferoxamine, deferasirox and deferiprone. Which one, how, and in what intensity are decisions for the prescribing clinician, and they rest on exactly the data described in this article.

The logic runs roughly like this. A rising ferritin trend or a higher liver iron on MRI suggests the current regimen is not keeping pace with transfusions. Cardiac iron creeping into the concerning range typically shifts the team’s priorities toward the heart, because chelators differ in how effectively they reach heart muscle. Low or falling iron, on the other hand, can prompt a step back, since over-chelation carries its own hazards. The same review also monitors the medicines themselves: kidney function, liver enzymes, blood counts, hearing and vision are all checked because chelators can affect them.

In the days after a review, blood results usually return first, followed by imaging reports over the following week or two. The team then meets or writes to you with a plan: continue, adjust or investigate further. If a hormone deficiency is found, an endocrinology referral typically follows; if liver scarring is suspected, a hepatology opinion.

What the weeks after that look like is mostly patience. Ferritin moves over months, not days, and heart iron clears far more slowly than it accumulates, improvement is judged across successive scans rather than between consecutive blood draws. A change in therapy is therefore an experiment whose answer arrives at the next review, which is another reason the reviews must keep happening.

What people often get wrong about thalassemia monitoring

Years of clinic conversations produce a fairly consistent list of misunderstandings. Correcting them is part of good care.

“My ferritin is fine, so my heart must be fine.” Ferritin tracks total body iron roughly and heart iron poorly. Cardiac MRI exists precisely because normal ferritin and a loaded heart can coexist.

“I feel well, so the MRI can wait.” Organ iron is silent until it is not. Feeling well is the expected state during the years when screening does its most useful work.

“Chelation replaces monitoring.” Chelation is the treatment; monitoring is how anyone knows whether it is working, whether it is enough, and whether it is causing side effects. One without the other is flying blind.

“Cutting iron from my diet will fix this.” For transfused people, dietary iron is a small contributor next to transfusion iron; sensible eating is reasonable, restrictive diets are not. For non-transfused people the gut matters more, and clinicians usually advise against iron supplements unless a deficiency is proven, but no diet substitutes for measurement.

“Puberty came normally, so my hormones are safe.” Pituitary and thyroid function can decline later in adulthood as iron accumulates, which is why endocrine tests continue at every age.

“MRI means radiation and dye.” T2* iron measurement uses magnetic fields, not X-rays, and typically requires no contrast injection. The main demands are lying still and tolerating an enclosed space.

“Carriers need the same checks.” People with thalassemia trait do not accumulate iron and are not usually enrolled in organ screening. Their needs are counseling and avoiding unnecessary iron, not scans.

The thread running through all of these is the same: the numbers, not the sensations, tell the story.

Questions to ask your care team

A screening review generates a lot of paper. These questions help turn it into a shared understanding rather than a stack of results.

  • Which organs were checked this time, and which were not, and why?
  • What is my current liver iron and heart iron, and how have they changed since the last scan?
  • Is my ferritin trend moving in the direction we want, or are we relying on the trend because imaging is pending?
  • Have any hormone results changed, and do any need repeating or a specialist opinion?
  • Are my iron-removal medicines being adjusted on the basis of these results, and what would prompt a further change?
  • What side-effect monitoring is in place for my current chelator, and which symptoms should I report between visits?
  • When is my bone density due, and is vitamin D being tracked?
  • Have I been tested for hepatitis B and C, and am I up to date with recommended vaccinations, especially if my spleen has been removed?
  • If I am planning a pregnancy, what assessments should happen first?
  • Who do I contact between reviews if something feels wrong, and who coordinates my care across hematology, cardiology and endocrinology?

Two further suggestions. Ask for copies of your MRI iron values and keep them; moving cities, changing insurers or transferring from pediatric to adult services goes far more smoothly when your own history travels with you. And if the review falls at a busy point in life, exams, a new job, a new baby, say so, and ask how the schedule can be adapted rather than letting it lapse. A postponed appointment is a decision, and it deserves to be made deliberately with the people who know your iron numbers.

When to call your doctor

Scheduled screening is designed to catch problems before symptoms. Between reviews, certain changes should not wait for the next appointment.

Contact your thalassemia team promptly, or seek emergency care, if you notice any of the following:

  • Palpitations, a racing or irregular heartbeat, fainting or near-fainting, possible iron-related rhythm disturbance.
  • New breathlessness at rest, when lying flat or on mild exertion, or swelling of the ankles or abdomen, possible heart strain or pulmonary hypertension.
  • Chest pain, sudden severe headache, weakness on one side, slurred speech, or a painful swollen calf, possible cardiac event, stroke or blood clot, all of which need emergency assessment.
  • Yellowing of the skin or eyes, dark urine with pale stools, vomiting blood, black stools or new confusion, possible liver decompensation or bleeding.
  • Excessive thirst, frequent urination, unexplained weight loss or blurred vision, possible new or worsening diabetes.
  • Tingling around the mouth or fingertips, muscle cramps or a seizure, possible low calcium from parathyroid failure.
  • Fever, particularly if your spleen has been removed, overwhelming infection can develop within hours and is a medical emergency.
  • Ringing in the ears, hearing change, visual disturbance, severe abdominal pain, or a marked drop in urine output while taking a chelator, possible medicine side effects that the prescribing team needs to know about at once.

Less urgently, tell your team about missed periods, a stalled growth spurt in a child, persistent fatigue that is new for you, or a missed or postponed review. None of these are reasons to change your own treatment; they are reasons to prompt the people who can.

Iron-related complications are treatable when caught early. The team that follows you has seen these patterns many times, and calling with a false alarm is a far better outcome than waiting with a real one.

Frequently asked questions

What are the major symptoms of thalassemia?

The main symptoms come from anemia: fatigue, weakness, pale or yellowish skin, slow growth in children, an enlarged spleen causing abdominal swelling, and dark urine, according to Mayo Clinic. Severe forms usually show within the first two years of life. The later complications of iron overload, heart, liver and hormone problems, typically cause no symptoms until advanced, which is why scheduled screening exists.

Can thalassemia get worse with age?

The gene change stays the same, but the burden accumulates. Transfused iron, hormone loss, bone thinning and heart strain add up over decades, and non-transfused forms often reveal complications only in adulthood. Structured monitoring and consistent iron-removal therapy substantially change that trajectory, which is why the handover from pediatric to adult care is a critical time not to lose contact with a specialist team.

What are the typical facial features of patients with thalassemia major?

Historically, overworked bone marrow expanding inside the skull and facial bones could broaden the forehead and cheekbones and alter jaw and tooth alignment. These changes arise when transfusion starts late or is given sparingly. Where regular transfusion begins early and keeps hemoglobin steady, the marrow does not over-expand and such features are far less common. They reflect the history of treatment, not the person.

What does a thalassemia test diagnose?

Diagnostic testing establishes whether someone has thalassemia and which type. A complete blood count shows small, pale red cells; iron studies rule out iron deficiency; hemoglobin electrophoresis identifies the alpha or beta pattern; and DNA testing pinpoints the gene change. This is separate from complication screening, which uses MRI, echocardiography and hormone panels to track what the condition is doing to organs over time.

What is a cardiac MRI for thalassemia, and does it involve radiation?

It is a magnetic scan that measures iron in heart muscle using a technique called T2*, which detects how quickly a magnetic signal fades in iron-laden tissue. It uses no X-rays and usually no contrast injection. The scan requires lying still inside the scanner for a period; the result gives the team a direct heart-iron value that ferritin alone cannot provide.

What are the most common thalassemia complications in adults?

Iron-related problems dominate: heart failure and rhythm disturbances, liver scarring, and hormone deficiencies including hypogonadism, diabetes, hypothyroidism and hypoparathyroidism. Osteoporosis is common. People with non-transfused thalassemia more often develop pulmonary hypertension, blood clots and leg ulcers. The NHS and NHLBI both describe these as the main long-term risks, and they are the targets of routine screening.

Why is my ferritin normal but my MRI shows iron?

Ferritin is an indirect marker that responds to inflammation, infection and liver health as well as iron, and it correlates poorly with heart iron in particular. MRI measures iron in the organ itself. A mismatch is common and is exactly why direct imaging is part of screening. Your team will interpret both results together rather than trusting either alone.

Do people with thalassemia trait need complication screening?

Usually not. Carriers have one altered gene, mild or no anemia, and do not accumulate iron, so they do not develop the organ complications seen in thalassemia major or intermedia. What carriers do benefit from is genetic counseling before having children and avoiding iron supplements unless a deficiency is proven, since their small red cells can be mistaken for iron deficiency.

Can hormone problems from thalassemia be reversed?

It depends on how early they are found and how much gland tissue remains. Some deficiencies improve when iron is brought down; others are permanent but manageable with hormone replacement or glucose management prescribed by an endocrinologist. This uncertainty is the strongest argument for annual endocrine blood tests: the earlier a decline is detected, the more options the treating team has.

How often are heart and liver checks done in thalassemia?

There is no single universal interval. The treating team sets a repeating schedule based on transfusion history, age and previous results, and shortens it when iron is high or organ function has changed. Blood tests such as ferritin are checked frequently; imaging is repeated less often. Ask your team for your personal schedule and what would prompt an earlier scan.

References

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.

Dr. Şule Eren
Dr. Şule Eren, MD
Author
View profile →
Published November 15, 2026
Keep Reading

More from the Blog

We’re With You at Every Step

How can we help you today?

We value your privacy We use essential cookies to run this site and, with your consent, analytics cookies to understand how it is used and improve it. You can accept, reject, or choose what to allow. See our Cookie Policy.